You are here: Industry Insights > Horizon

News List

Alpine Immune, Horizon enter autoimmune disease research collaboration Pharmaceutical-Business-Review
December 21, 2021
Alpine Immune Sciences and Horizon Therapeutics have signed an exclusive licence and collaboration agreement to develop protein-based therapies to treat autoimmune and inflammatory diseases.
Arrowhead and Horizon enter up to $700m deal to develop RNAi drug pharmaceutical-technology
June 23, 2021
Arrowhead Pharmaceuticals and Horizon Therapeutics have entered a global partnership and licence agreement to develop the former’s ribonucleic acid interference (RNAi) therapeutic, ARO-XDH.
Horizon Therapeutics Buys EirGen Manufacturing Facility contractpharma
June 18, 2021
The 44,000 square foot facility in Ireland includes fill-finish and analytical laboratory capabilities with potential for site expansion.
AstraZeneca Competes Viela Divestment americanpharmaceuticalreview
March 18, 2021
AstraZeneca has completed the divestment of its 26.7% ownership in Viela Bio, as part of the proposed acquisition of Viela by Horizon Therapeutics. This follows the agreement to divest the shareholding on February 1, 2021.
AstraZeneca to Divest Viela Shareholding americanpharmaceuticalreview
February 02, 2021
AstraZeneca has agreed, subject to certain limited exceptions, to divest its 26.7% ownership in Viela Bio, as part of the proposed acquisition of Viela by Horizon Therapeutics.
Horizon bulks up sales force ahead of $750M inflammatory eye drug launch fiercepharma
June 28, 2019
Horizon Therapeutics—until recently known as Horizon Pharma—is headed for an FDA filing for its inflammatory eye drug teprotumumab. To prepare for the potential launch, the company has set out to expand its sales team.
Horizon bulks up sales force ahead of $750M inflammatory eye drug launch fiercepharma
June 28, 2019
Horizon Therapeutics—until recently known as Horizon Pharma—is headed for an FDA filing for its inflammatory eye drug teprotumumab. To prepare for the potential launch, the company has set out to expand its sales team.
Horizon completes enrollment in TED trial early pharmatimes
September 14, 2018
Horizon Pharma says it has completed enrollment in a confirmatory Phase III trial of teprotumumab in patients living with moderate-to-severe active thyroid...
Clinigen buys global rights to Horizon’s Imukin pharmatimes
July 27, 2018
The UK’s Clinigen Group has bought global rights to rare disease therapy Imukin from Horizon Pharma, for an undisclosed amount.
Horizon expands agreement with Roche Diagnostics pharmatimes
December 19, 2017
Cambridge, UK-based Horizon Discovery has expanded its relationship with Roche Diagnostics with a new agreement to assist in the development of immunohistochemistry (IHC) assays.

Previous page 1 2 Next page